• Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

    12 days ago - By San Diego Biotechnology

    Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hours After Surgery -
    SAN DIEGO, Sept. 16, 2020 /PRNewswire/ - Heron Therapeutics, Inc. , a commercial-stage biote......
    Read more ...